Takuya Kobayakawa
Overview
Explore the profile of Takuya Kobayakawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
132
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kobayakawa T, Arioka M, Yamamoto K, Tsuji K, Tamamura H
Org Biomol Chem
. 2025 Feb;
PMID: 39945507
An efficient method for diastereo-controlled synthesis of ()-fluoroalkene dipeptide isosteres (FADIs) was developed. Two chiral centers were constructed by applying our synthetic methodology for chloroalkene dipeptide isosteres (CADIs) using Ellman's...
2.
Higashi-Kuwata N, Bulut H, Hayashi H, Tsuji K, Ogata-Aoki H, Kiso M, et al.
PNAS Nexus
. 2025 Jan;
4(1):pgae578.
PMID: 39831159
We identified a 5-fluoro-benzothiazole-containing small molecule, TKB272, through fluorine-scanning of the benzothiazole moiety, which more potently inhibits the enzymatic activity of SARS-CoV-2's main protease (M) and more effectively blocks the...
3.
Shinohara K, Kobayakawa T, Tsuji K, Takamatsu Y, Mitsuya H, Tamamura H
Eur J Med Chem
. 2024 Oct;
280:116963.
PMID: 39442336
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), has not yet been eradicated. SARS-CoV-2 has two types of proteases, a main protease (M) and a...
4.
Kobayakawa T, Tsuji K, Tamamura H
Bioorg Med Chem
. 2024 Jul;
110:117811.
PMID: 38959684
Ample biologically active peptides have been found, identified and modified for use in drug discovery to date. However, several factors, such as low metabolic stability due to proteolysis and non-specific...
5.
Ishii T, Kobayakawa T, Matsuda K, Nigorikawa K, Bolah P, Noborio A, et al.
ACS Infect Dis
. 2024 May;
10(6):2250-2261.
PMID: 38771724
Toward human immunodeficiency virus type-1 (HIV-1) cure, cells latently infected with HIV-1 must be eliminated from people living with HIV-1. We previously developed a protein kinase C (PKC) activator, diacylglycerol...
6.
Kobayakawa T, Takano H, Ishii T, Bolah P, Tsuji K, Ohashi N, et al.
Chem Pharm Bull (Tokyo)
. 2024 Mar;
72(3):311-312.
PMID: 38494724
An improvement of the two-photon excitation was achieved using 8-azacoumarin-type caged compounds, which showed large values of the two-photon uncaging action cross-section (δ >0.1 Goeppert-Mayer (GM)). In particular, the 7-hydroxy-6-iodo-8-azacoumarin...
7.
Kobayakawa T, Yokoyama M, Tsuji K, Boku S, Kurakami M, Fujino M, et al.
Chem Pharm Bull (Tokyo)
. 2024 Jan;
72(1):41-47.
PMID: 38171903
The capsid of human immunodeficiency virus type 1 (HIV-1) forms a conical structure by assembling oligomers of capsid (CA) proteins and is a virion shell that encapsulates viral RNA. The...
8.
Tsuji K, Kobayakawa T, Ishii T, Higashi-Kuwata N, Azuma C, Shinohara K, et al.
Chem Pharm Bull (Tokyo)
. 2023 Dec;
71(12):879-886.
PMID: 38044140
In the development of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) drugs, its main protease (M), which is an essential enzyme for viral replication, is a promising target. To date,...
9.
Kobayakawa T, Amano M, Nakayama M, Tsuji K, Ishii T, Miura Y, et al.
RSC Med Chem
. 2023 Oct;
14(10):1973-1980.
PMID: 37859721
Hepatitis B is a viral hepatitis, which is caused by infection of hepatitis B virus (HBV). This disease progresses to chronic hepatitis, cirrhosis and liver cancer. To treat hepatitis B,...
10.
Tsuji K, Ishii T, Kobayakawa T, Higashi-Kuwata N, Shinohara K, Azuma C, et al.
J Med Chem
. 2023 Sep;
66(19):13516-13529.
PMID: 37756225
The main protease (M) of SARS-CoV-2 is an attractive target for the development of drugs to treat COVID-19. Here, we report the design, synthesis, and structure-activity relationship (SAR) studies of...